<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340950</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH092225</org_study_id>
    <secondary_id>1R01MH092225-01</secondary_id>
    <nct_id>NCT01340950</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China</brief_title>
  <official_title>Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This primary aim of the project is to determine the association between antiretroviral&#xD;
      therapy that better distributes into the central nervous system and prevention of&#xD;
      HIV-associated neurocognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advances in treatment have transformed HIV disease to a chronic illness in most individuals&#xD;
      in the U.S. The most common central nervous system (CNS) complication of chronic HIV disease&#xD;
      is HIV-associated neurocognitive disorder (HAND). In the U.S., HAND prevalence estimates&#xD;
      range up to 55% of treated individuals. HAND is also common outside the U.S. For example, our&#xD;
      prior project in China identified that more than a third of nearly 150 treated HIV(+)&#xD;
      individuals in Anhui and Yunnan provinces had HAND. Data such as these support that the&#xD;
      benefits of antiretroviral therapy (ART) can be incomplete, with many patients not returning&#xD;
      to normal neurocognitive performance or, worse, developing new neurocognitive impairment&#xD;
      while taking ART.&#xD;
&#xD;
      One explanation for this is the limited penetration of some antiretrovirals into the nervous&#xD;
      system. Recent reports have identified that worse antiretroviral penetration characteristics&#xD;
      are associated with worse control of HIV replication and worse neurocognitive performance.&#xD;
      Most reports, however, have focused on treatment - rather than prevention - of HAND. Like&#xD;
      many other medical conditions, prevention of HAND may be a more cost-effective public health&#xD;
      goal than treating disease that has already occurred.&#xD;
&#xD;
      We are building on our prior work in China by performing a phase 4, randomized, controlled&#xD;
      clinical trial of the safety and effectiveness of ART that differs in its penetration&#xD;
      characteristics in 250 ART-naive individuals who have normal neurocognitive performance. The&#xD;
      primary objective will be to determine the effects of better penetrating (BP) ART&#xD;
      (zidovudine-lamivudine-nevirapine) compared with worse penetrating (WP) ART&#xD;
      (tenofovir-lamivudine-efavirenz) on the prevention of HAND. We hypothesize that volunteers&#xD;
      who are randomized to BP-ART will be less likely to neurocognitively decline over 96 weeks of&#xD;
      observation than those who are randomized to WP-ART. The secondary objective will be to&#xD;
      assess the influence on study outcomes of two conditions: persistent immune activation and&#xD;
      viral hepatitis. In an exploratory aim, the project will also assess the influence on study&#xD;
      outcomes of a concise panel of drug disposition-associated genetic polymorphisms.&#xD;
&#xD;
      Demonstrating that HAND can be prevented by using BP-ART should influence HIV treatment&#xD;
      guidelines in the U.S., China, and elsewhere and ultimately lead to preservation of normal&#xD;
      neurocognitive functioning in people afflicted with HIV/AIDS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in neuropsychological performance at 96 weeks</measure>
    <time_frame>96 weeks</time_frame>
    <description>Comparison of decline in NP performance between treatment groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>HIV Infections</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Better-Penetrating ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Worse-Penetrating ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine-lamivudine-nevirapine</intervention_name>
    <description>96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily</description>
    <arm_group_label>Better-Penetrating ART</arm_group_label>
    <other_name>Retrovir, Epivir, Viramune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir-lamivudine-efavirenz</intervention_name>
    <description>96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily</description>
    <arm_group_label>Worse-Penetrating ART</arm_group_label>
    <other_name>Viread, Epivir, Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women of at least 18 years of age.&#xD;
&#xD;
          -  Ability and willingness of subject to give written informed consent.&#xD;
&#xD;
          -  HIV-1 infection, as documented by enzyme-linked immunosorbent assay (ELISA) and&#xD;
             confirmed by Western blot at any time prior to study entry. Plasma HIV-1 RNA is&#xD;
             acceptable as an alternative confirmatory test.&#xD;
&#xD;
          -  Antiretroviral drug-naïve, defined as ≤10 days of ART at any time prior to entry.&#xD;
&#xD;
          -  Clinical HIV-1 RNA ≥1000 copies/mL obtained within 90 days of study screening.&#xD;
&#xD;
          -  Clinical blood CD4+ cell count &lt; 350/mm3 (for men) or &lt;250/mm3 (for women) within 60&#xD;
             days of study screening.&#xD;
&#xD;
          -  Performance within the expected normal range on the project's comprehensive,&#xD;
             standardized battery of neuropsychological tests within 4 weeks.&#xD;
&#xD;
          -  For women of child-bearing potential (WOCBP), negative serum or urine pregnancy test&#xD;
             at screening and within 48 hours prior to initiating study medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious illness requiring systemic treatment or hospitalization within 4 weeks.&#xD;
&#xD;
          -  Unacceptable laboratory values obtained within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Untreated syphilis.&#xD;
&#xD;
          -  Child Pugh Class C hepatic impairment.&#xD;
&#xD;
          -  Active Hepatitis B Virus infection.&#xD;
&#xD;
          -  Known allergy/sensitivity to study drugs or their formulations.&#xD;
&#xD;
          -  Severe or untreated conditions that could affect NP test performance.&#xD;
&#xD;
          -  Such conditions include but are not limited to current substance use disorder, poorly&#xD;
             controlled diabetes, uncontrolled seizure disorder, and any progressive CNS disorder&#xD;
             (e.g., multiple sclerosis, CNS neoplasm) and evidence of acute intoxication or&#xD;
             withdrawal, in the opinion of the study clinician.&#xD;
&#xD;
          -  Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine,&#xD;
             systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Currently breast-feeding.&#xD;
&#xD;
          -  Requirement for any medications that have an absolute contraindication with any study&#xD;
             drugs. In addition, we will exclude people taking rifampin.&#xD;
&#xD;
          -  Current imprisonment or involuntary incarceration in a medical facility for&#xD;
             psychiatric or physical illness.&#xD;
&#xD;
          -  Prior use of nucleoside analogues, such as tenofovir, adefovir, or lamivudine, for&#xD;
             treatment of hepatitis B for greater than 8 weeks while the subject was known to be&#xD;
             HIV-infected.&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigators, would compromise the&#xD;
             subject's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott L Letendre, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://id.ucsd.edu/international/china.shtml</url>
    <description>UCSD Division of Infectious Diseases International Program - China</description>
  </link>
  <link>
    <url>http://hnrc.hivresearch.ucsd.edu/</url>
    <description>UCSD HIV Neurobehavioral Research Program</description>
  </link>
  <link>
    <url>http://www.chinacdc.cn</url>
    <description>China Center for Disease Control and Prevention</description>
  </link>
  <link>
    <url>http://www.bjditan.org/about_dicid_about_ditan_hospital.html</url>
    <description>Beijing Ditan Hospital</description>
  </link>
  <reference>
    <citation>Heaton RK, Cysique LA, Jin H, Shi C, Yu X, Letendre S, Franklin DR, Ake C, Vigil O, Atkinson JH, Marcotte TD, Grant I, Wu Z; San Diego HIV Neurobehavioral Research Center Group. Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol. 2008 Nov;14(6):536-49. doi: 10.1080/13550280802378880. Erratum in: J Neurovirol. 2010 Mar;16(2):185-8.</citation>
    <PMID>18991068</PMID>
  </reference>
  <reference>
    <citation>Cysique LA, Letendre SL, Ake C, Jin H, Franklin DR, Gupta S, Shi C, Yu X, Wu Z, Abramson IS, Grant I, Heaton RK; HIV Neurobehavioral Research Center group. Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS. 2010 Apr 24;24(7):983-90. doi: 10.1097/QAD.0b013e32833336c8.</citation>
    <PMID>20299964</PMID>
  </reference>
  <reference>
    <citation>Spector SA, Singh KK, Gupta S, Cystique LA, Jin H, Letendre S, Schrier R, Wu Z, Hong KX, Yu X, Shi C, Heaton RK; HNRC Group. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS. 2010 Jun 19;24(10):1471-9. doi: 10.1097/QAD.0b013e328339e25c.</citation>
    <PMID>20442634</PMID>
  </reference>
  <reference>
    <citation>Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.</citation>
    <PMID>18195140</PMID>
  </reference>
  <reference>
    <citation>Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ; HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004 Sep;56(3):416-23.</citation>
    <PMID>15349869</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Scott Letendre</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>Neuropsychological Tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared in conference presentations and peer-reviewed publications. Data will also be made available on approval of requests for appropriate use.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

